Search
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalRitlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe a...
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties. . Mycophenolic acid is ...
Lupus Nephritis
go.drugbank.com/conditions/DBCOND0001366Ruclosporin
go.drugbank.com/drugs/DB21199ExperimentalThe usage of the INN stem '-(clo)sporin' in the name indicates that Ruclosporin is a cyclosporine derivative. Ruclosporin has a monoisotopic molecular weight of 1330.92 Da.
Liver Transplant Rejection
go.drugbank.com/conditions/DBCOND0054228